Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • 1 July 2023 to 30 September 2024
  • Awards: Pump-priming Awards

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and linked to different variants in genes encoding sarcomeric proteins. Energy deficiency plays an important role in HCM, which may favourably respond to substrate manipulation and metabolic therapies. However, investigations on metabolic alterations in HCM are scarce and the impact of different sarcomeric variants on cardiac energetics remains unknown. We recently demonstrated disturbances of cellular metabolism, oxygen consumption rate, and contractility in genetically modified human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with sarcomeric mutations. To better understand altered energetic states and links to pathogenic sarcomeric variants, we plan to perform phenotyping via proteomics-based computational modeling of myocardial metabolism in iPSC-CMs obtained from HCM patients. This data will be correlated with advanced cardiac magnetic resonance imaging of myocardial function, energetics, and oxygenation. We do this to identify therapeutic targets in HCM and nucleate an immortalized cell biobank of patient iPSCs.


Titin-GFP labelled iPSC-CMs displaying clear z-disk striations of the cardiac sarcomere, allowing direct visualization of contractility.